[1]. R. Frederick, Textbook of Military Medicine, Published by the Office of Surgeon General Department of Army, USA, p.pp. 1411997.
[2]. J. Millerioux, et al, "Evaluation of
In Vitro Tests to Assess the Efficacy of Formulations as Topical Skin Protectants against Organophosphorus Compounds," Toxicol. in Vitr., Vol. 23, pp. 127–133, 2009.
[3]. J. Millerioux, et al, "
In Vitro Selection and Efficacy of Topical Skin Protectants against the Nerve Agent VX," Toxicol. in Vitr., Vol. 23, pp. 539–545, 2009.
[4]. C. Bignon, et al, "Barrier Cream Based on CeO
2 Nanoparticles Grafted Polymer as an Active Compound against the Penetration of Organophosphates," Chemico-Biological Inter., Vol. 267, pp. 17–24, 2017.
[5]. Ernest H. Braue Jr., Development of an Active Topical Skin Protectant, USAMRICD-TR-16-03. pp. 1–180, Feb. 2016.
[6]. Sandra L. Fox, et al, Emergency First Responders, Experience with Colorimetric Detection Methods,” Idaho National Laboratory U.S. Department of Homeland Security Under DOE Idaho Operations Office Contract DE-AC07-05ID14517. pp. 1–33, 2007;10..
[7]. S. W. Kim, et al, "Study on the Formulations for Topical Skin Protectant against Liquid-Phase Chemical Warfare Agents," Journal of the Korea Institute of Military Science and Technology, Vol. 25(2):pp. 210–217, 2022.
[8]. Carl T. Olson, et al, "Evaluation of Compounds as Barriers to Dermal Penetration of Organophosphates using Acetylcholinesterase Inhibition," Toxicol. Lett., Vol. 55, pp. 325–334, 1991.
[9]. William G. Reifenra, et al, "A Comparison of in Vitro Skin-Penetration Cells," J. Pharm. Sci., Vol. 83(9):pp. 1229–1233, Sep. 1994.
[10]. OECD Guideline for the Testing of Chemicals. Skin Absorption: In Vitro Method, OECD/OCDE 428 Adopted :13 April. 2004.
[11]. S. Akhter, et al, "Automated Diffusion Apparatus for Studying Skin Penetration," Int. J. Pharm., Vol. 21, pp. 17–26, 1984.
[12]. R. Bronaugh, et al, "Methods for
In Vitro Percutaneous Absorption Studies," J. Pharm. Sci., Vol. 74, pp. 64–67, 1985.
[13]. W. Addicks, et al, "Validation of a Flow-Through Diffusion Cell for use in Transdermal Research," Pharm. Res., Vol. 4, pp. 337–341, 1987.
[14]. J. Davies, et al, "Further Development of an
In Vitro Model for Studying the Penetration of Chemicals Through Compromised Skin," Toxicol. in Vitr., Vol. 38, pp. 101–107, 2017.
[15]. Hoo-Kyun Choi, et al, "Mathematical Analysis and Optimization of a Flow-Through Diffusion Cell System," Pharm. Res., Vol. 11(4):pp. 595–599, 1994.
[16]. H. Dalton, et al, "Absorption of the Nerve Agent VX (
O-ethyl-S-[2(di-isopropylamino)ethyl] methyl phosphonothioate) Through Pig, Human and Guinea Pig Skin
In Vitro," Toxicol. in Vitr., Vol. 20, pp. 1532–1536, 2006.
[17]. G. A. Simon, et al, "The Pig as an Experimental Animal Model of Percutaneous Permeation in Man," Skin Pharmacol. Appl. Skin Physiol., Vol. 13, pp. 229–234, 2000.
[18]. C. R. Atchinson, et al, "Development of a Guinea Pig Model for Low Dose, Long Term Exposure to Organophosphorous Nerve Agent," Toxicol. Mech. Meth., Vol. 14, pp. 183–194, 2004.
[19]. J. Wetherell, et al, "Physostigmine and Hyoscine Improves Protection against the Lethal and Incapacitating Effects of Nerve Agent Poisoning in the Guinea Pig," Neurotoxicol., Vol. 23, pp. 341–349, 2002.
[20]. W. J. Addicks, et al, "Validation of a Flow- Through Diffusion Cell for use in Transdermal Research," Pharm. Res., Vol. 4, pp. 337–341, 1987.
[21]. G. A. Simon, et al, "Comparative Evaluation of Rivastigmine Permeation from a Transdermal System in the Franz Cell using Synthetic Membranes and Pig Ear Skin with
in Vivo-In Vitro Correlation," Inter. J. Pharm., Vol. 512, pp. 234–241, 2016.
[22]. FDA. 1997;Guidance for Industry: SUPAC-SS Nonsterile Semisolid Dosage Forms: Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls In Vitro Release Testing and In Vivo Bioequivalence Documentation.
[23]. T. Lalain, et al, Chemical Warfare Agents Decontamination Efficiency Testing Large-Scale Chamber mVHP Decontamination Evaluation, ECBC-TR-731, Edgewood Chemical and Biological Center. 2010.
[24]. K. Lakshmi, et al, "ZnO/PAN Nanofiber Catalyst for Photodegradation of Methyl Paraoxon and Its Toxicological Evaluation Utilizing Early Life Stages of Zebra Fish," Chem. Eng. J., Vol. 357, pp. 724–736, 2019.
[25]. L. SHANNON, et al, "Review of Chemical Warfare Agent Simulants for the Study of Environmental Behavior," Critical Rev. in Environ. Sci. and Tech., Vol. 38, pp. 112–136, 2008.
[26]. L. Song, et al, "Photothermal Graphene Fabrics for Ultra Fast Catalytic Degradation of Chemical Warfare Agent Simulants," J. Hazard. Mater., Vol. 393, pp. 122–132, 2020.
[27]. C. A. Moore, et al, "Use of a Human Skin
In Vitro Model to Investigate the Influence of ‘Every- Day’ Clothing and Skin Surface Decontamination on the Percutaneous Penetration of Organophosphates," Toxicol. Lett., Vol. 229, pp. 257–264, 2014.
[28]. C. A. Moore, et al, "Percutaneous Absorption and Distribution of Organophosphates (Chlorpyrifos and Dichlorvos) Following Dermal Exposure and Decontamination Scenarios using
In Vitro Human Skin Model," Toxicol. Lett., Vol. 229, pp. 66–72, 2014.
[29]. S. Dachir, et al, "Dermostyx (IB1)-High Efficacy and Safe Topical Skin Protectant against Percutaneous Toxic Agents," Chemico-Biological, Inter., Vol. 267, pp. 25–32, 2017.
[30]. T. Kadar, et al, "A Topical Skin Protectant against Chemical Warfare Agents," Israel Med. Ass. J., Vol. 5, pp. 717–719, Oct. 2003.
[31]. N. Ophir, et al, "Using the Skin Protective Lotion IB1 as a Substitute for Chemical Protective Gloves," Am. J. Emer. Med., Vol. 34, pp. 1986–1990, 2016.